MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine

Biomaterials

Volumn 35, Issue 5, 2014, Pages 1744-1754

  Moon, Hyung Ho ^a   Joo, Min Kyung ^b   Mok, Hyejung ^c   Lee, Minhyung ^d   Hwang, Ki Chul ^a   Kim, Sung Wan ^e   Jeong, Ji Hoon ^f   Choi, Donghoon ^a   Kim, Sun Hwa ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Konkuk University   (South Korea)

^d Hanyang University   (South Korea)

^e UNIVERSITY OF UTAH   (United States)

^f Sungkyunkwan University   (South Korea)

Author keywords

Cell based gene therapy; Facial amphipathic bile acid; Mesenchymal stem cells; Myocardial infarction; Vascular endothelial growth factor

Indexed keywords

BILE ACID; CELL-BASED; MESENCHYMAL STEM CELL; MYOCARDIAL INFARCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR;

BODY FLUIDS; CELL ENGINEERING; ENDOTHELIAL CELLS; FLOWCHARTING; GENE THERAPY; GENE TRANSFER; LIPOSOMES; MOLECULAR BIOLOGY; RATS; REPAIR; TISSUE REGENERATION;

CELL CULTURE;

BILE ACID; LIPOFECTAMINE; POLYETHYLENEIMINE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL BASED GENE THERAPY; CELL CULTURE; CONTROLLED STUDY; GENE THERAPY; HEART INFARCTION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGENERATIVE MEDICINE;

RATTUS;

CELL-BASED GENE THERAPY; FACIAL AMPHIPATHIC BILE ACID; MESENCHYMAL STEM CELLS; MYOCARDIAL INFARCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ANIMALS; BILE ACIDS AND SALTS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; MALE; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; POLYETHYLENEIMINE; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890154858     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.019     Document Type: Article

References (43)

1. Assmus B., Schachinger V., Teupe C., Britten M., Lehmann R., Dobert N., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002, 106:3009-3017.
2. Segers V.F.M., Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008, 451:937-942.
3. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004, 95:9-20.
4. Hass R., Kasper C., Bohm S., Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011, 9:12.
5. Li Q., Wang Y., Deng Z.F. Pre-conditioned mesenchymal stem cells: a better way for cell-based therapy. Stem Cell Res Ther 2013, 4:63.
6. Cheng Z., Ou L., Zhou X., Li F., Jia X., Zhang Y., et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008, 16:571-579.
7. Kumar S., Chanda D., Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther 2008, 15:711-715.
8. Gnecchi M., He H., Liang O.D., Melo L.G., Morello F., Mu H., et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005, 11:367-368.
9. Mosca J.D., Hendricks J.K., Buyaner D., Davis-Sproul J., Chuang L.C., Majumdar M.K., et al. Mesenchymal stem cells as vehicles for gene delivery. Clin Orthop Relat Res 2000, S71-S90.
10. De Smedt S.C., Demeester J., Hennink W.E. Cationic polymer based gene delivery systems. Pharm Res 2000, 17:113-126.
11. Reiser J., Zhang X.Y., Hemenway C.S., Mondal D., Pradhan L., La Russa V.F. Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther 2005, 5:1571-1584.
12. Li Y.H., Zhang R., Qiao H.F., Zhang H.P., Wang Y.F., Yuan H.F., et al. Generation of insulin-producing cells from PDX-1 gene-modified human mesenchymal stem cells. JCell Physiol 2007, 211:36-44.
13. Song L., Chau L., Sakamoto Y., Nakashima J., Koide M., Tuan R.S. Electric field-induced molecular vibration for noninvasive, high-efficiency DNA transfection. Mol Ther 2004, 9:607-616.
14. Haleem-Smith H., Derfoul A., Okafor C., Tuli R., Olsen D., Hall D.J., et al. Optimization of high-efficiency transfection of adult human mesenchymal stem cells invitro. Mol Biotechnol 2005, 30:9-20.
15. Koren E., Torchilin V.P. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 2012, 18:385-393.
16. Fonseca S.B., Pereira M.P., Kelley S.O. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009, 61:953-964.
17. Futaki S., Nakase I., Taclokoro A., Takeuchi T., Jones A.T. Arginine-rich peptides and their internalization mechanisms. Biochem Soc Trans 2007, 35:784-787.
18. Nakase I., Akita H., Kogure K., Graslund A., Langel U., Harashima H., et al. Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc Chem Res 2012, 45:1132-1139.
19. Jang Y.L., Yun U.J., Lee M.S., Kim M.G., Son S., Lee K., et al. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. Int J Pharm 2012, 434:488-493.
20. Chae S.Y., Kim H.J., Lee M.S., Jang Y.L., Lee Y., Lee S.H., et al. Energy-independent intracellular gene delivery mediated by polymeric biomimetics of cell-penetrating peptides. Macromol Biosci 2011, 11:1169-1174.
21. Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009, 157:195-206.
22. Carelli V., Dicolo G., Nannipieri E., Serafini M.F. Bile-acids as enhancers of steroid penetration through excised hairless mouse skin. Int J Pharm 1993, 89:81-89.
23. Kim S.H., Moon H.H., Kim H.A., Hwang K.C., Lee M., Choi D. Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury. Mol Ther 2011, 19:741-750.
24. Kim D., Lee D., Jang Y.L., Chae S.Y., Choi D., Jeong J.H., et al. Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA delivery in vascular smooth muscle cells. Eur J Pharm Biopharm 2012, 81:14-23.
25. Tae S.K., Lee S.H., Park J.S., Im G.I. Mesenchymal stem cells for tissue engineering and regenerative medicine. Biomed Mater 2006, 1:63-71.
26. Noiseux N., Gnecchi M., Lopez-Ilasaca M., Zhang L., Solomon S.D., Deb A., et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 2006, 14:840-850.
27. Borden B.A., Yockman J., Kim S.W. Thermoresponsive hydrogel as a delivery scaffold for transfected rat mesenchymal stem cells. Mol Pharm 2010, 7:963-968.
28. Robey T.E., Saiget M.K., Reinecke H., Murry C.E. Systems approaches to preventing transplanted cell death in cardiac repair. JMol Cell Cardiol 2008, 45:567-581.
29. Shake J.G., Gruber P.J., Baumgartner W.A., Senechal G., Meyers J., Redmond J.M., et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002, 73:1919-1925. discussion 26.
30. Yockman J.W., Choi D., Whitten M.G., Chang C.W., Kastenmeier A., Erickson H., et al. Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. Gene Ther 2009, 16:127-135.
31. Chen Y., Ho D.M., Gottlieb C.R., Kahne D., Bruck M.A. Facial amphiphiles. JAm Chem Soc 1992, 114:7319-7320.
32. Rösler A., Vandermeulen G.W.M., Klok H.A. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2012, 64:270-279.
33. Walker S., Sofia M.J., Kakarla R., Kogan N.A., Wierichs L., Longley C.B., et al. Cationic facial amphiphiles: a promising class of transfection agents. Proc Natl Acad Sci U S A 1996, 93:1585-1590.
34. Kish P.E., Tsume Y., Kijek P., Lanigan T.M., Hilfinger J.M., Roessler B.J. Bile acid-oligopeptide conjugates interact with DNA and facilitate transfection. Mol Pharm 2007, 4:95-103.
35. Hoffmann J., Glassford A.J., Doyle T.C., Robbins R.C., Schrepfer S., Pelletier M.P. Angiogenic effects despite limited cell survival of bone marrow-derived mesenchymal stem cells under ischemia. Thorac Cardiovasc Surg 2010, 58:136-142.
36. Jeong J.H., Kim S.H., Christensen L.V., Feijen J., Kim S.W. Reducible poly(amido ethylenimine)-based gene delivery system for improved nucleus trafficking of plasmid DNA. Bioconjug Chem 2010, 21:296-301.
37. Maltepe E., Saugstad O.D. Oxygen in health and disease: regulation of oxygen homeostasis-clinical implications. Pediatr Res 2009, 65:261-268.
38. Gao F., He T., Wang H., Yu S., Yi D., Liu W., et al. Apromising strategy for the treatment of ischemic heart disease: mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Can J Cardiol 2007, 23:891-898.
39. Tang J.M., Wang J.N., Zhang L., Zheng F., Yang J.Y., Kong X., et al. VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res 2011, 91:402-411.
40. Pons J., Huang Y., Arakawa-Hoyt J., Washko D., Takagawa J., Ye J., et al. VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun 2008, 376:419-422.
41. Deasy B.M., Feduska J.M., Payne T.R., Li Y., Ambrosio F., Huard J. Effect of VEGF on the regenerative capacity of muscle stem cells in dystrophic skeletal muscle. Mol Ther 2009, 17:1788-1798.
42. Levenberg S., Rouwkema J., Macdonald M., Garfein E.S., Kohane D.S., Darland D.C., et al. Engineering vascularized skeletal muscle tissue. Nat Biotechnol 2005, 23:879-884.
43. Jiang B., Dong H.Y., Zhang Z.M., Wang W., Zhang Y.Q., Xu X.H. Hypoxic response elements control expression of human vascular endothelial growth factor(165) genes transferred to ischemia myocardium invivo and invitro. JGene Med 2007, 9:788-796.